NYSE · Biotechnology

Annovis Bio, Inc. (ANVS) Stock

$1.21 +3.42% NYSE: ANVS Healthcare

Valuation

MetricValue
Price$1.21
Market Cap$51.48M
P/E Ratio-0.67
P/B Ratio-10.58
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$5.50
52-Week Low$1.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-685.96%
ROA-224.73%
ROCE-315.92%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio5.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-15.0M$-26.0M$-45.0M$-27.0M$-30.0M
Net Profit$-14.0M$-25.0M$-56.0M$-25.0M$-29.0M
EPS$-1.90$-3.10$-6.23$-2.31$-1.40
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$46.0M$36.0M$10.0M$14.0M$21.0M
Total Liabilities$2.0M$8.0M$18.0M$5.0M$4.0M
Cash$46.0M$28.0M$6.0M$11.0M$20.0M
Borrowings$0$0$0$0$0

Latest News

Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial NYSE · Jul 7, 2026 Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease MT Newswires · Jul 7, 2026 Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease GlobeNewswire · Jul 7, 2026 Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer GlobeNewswire · Jul 1, 2026 Annovis Bio Regains NYSE Listing Compliance GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-9.0M$-17.0M$-40.0M$-22.0M$-26.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$38.0M$-17.0M$-23.0M$5.0M$9.0M
Free Cash Flow$-9.0M$-17.0M$-40.0M$-22.0M$-26.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.59
EV / EBITDA-0.66
FCF Yield-84.90%
Quick Ratio2.95
Interest Coverage-31.16
Return 1Y-34.33%
Return 3Y-87.26%
Return 5Y-98.31%

Ownership

Insiders Held8.26%
Institutions Held16.70%
Institutions Float Held18.21%
Institutional HolderSharesReport Date
Marshall Wace LLP1,187,4992026-03-31
Vanguard Capital Management LLC872,3812026-03-31
Two Sigma Investments, LP627,6592026-03-31
Renaissance Technologies, LLC347,6002026-03-31
Geode Capital Management, LLC247,5132026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATNMActinium Pharmaceuticals, Inc. (Delaware) $1.10 +1.85% 3.25 $34.51M 0.00%
BCAB $1.74 +0.00% -0.12 $2.88M 0.00%
BTAI $0.07 +0.00% -0.02 $2.28M 0.00%
CELUCelularity Inc. $1.56 +6.85% -0.51 $45.16M 0.00%
ELUTElutia, Inc. $0.82 -0.51% 0.60 $36.39M 0.00%

About Annovis Bio, Inc.

Annovis Bio, Inc. is led by CEO Maria L. Maccecchini, employs 8 people, headquartered in US, publicly traded since 2020.

Annovis Bio, Inc. (ANVS) stock trades at $1.21 with a market capitalization of $51.48M. The stock is valued at a price-to-earnings (P/E) ratio of -0.67, price-to-book of -10.58, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.04 and $5.50, and currently trades 78.0% below its 52-week high.

On profitability, Annovis Bio, Inc. generates a return on equity (ROE) of -685.96%, return on capital employed of -315.92%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides